NextVivo

Developer of an immune organoid technology intended to generate human cell and antibody candidate therapies by leveraging the immune system's natural defenses. The company's technology provides organoids that are miniature cell cultures that model the composition, structure, and function of human tissue and can uniquely recapitulate the humoral and cellular immune response outside of the body, enabling patients to test pre-clinical candidates on ex vivo human tissue models and identify the most effective therapies for clinical development.

Khosla Ventures

🏥 Healthcare